Confidential information

The law of confidentiality is often the best way of protecting trade secrets and valuable know-how where these are not otherwise adequately protected by other means (eg via intellectual property rights), or where using other types of protection is unattractive for commercial reasons.

Even if other types of rights exist (eg patent rights in the case of patented inventions), often the real value of an invention or new piece of technology does not lie just in the invention itself, but also in the associated know-how, training and guidance required to fully exploit it. Therefore, the law of confidentiality also helps to protect valuable information associated with (for instance) an invention, along with financial, customer and similar confidential information that a business holds.

Examples of items which might be considered confidential within a business include:

•
commercial records such as price lists, customer lists, details of customers, suppliers, business partners and relationships with regulators or other third parties
•
unpublished copyright works
•
mathematical formulae and manufacturing techniques, processes, designs, drawings and engineering
•
secure codes and algorithms
•
personal employee information such as compensation arrangements, benefits, hours or work etc

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

EFPIA leads healthcare associations in challenging ECHA's PFAS restriction assessment approach

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and eight other healthcare associations have raised concerns that the European Chemicals Agency (ECHA) will not conduct individual sector assessments for medicines as part of its proposed universal restriction on PFAS chemicals. While the healthcare sector remains within the restriction's scope, ECHA indicated that 'other medical applications' covering medicinal products and manufacturing will not be individually assessed during preparation of final opinions by the Risk Assessment Committee and Socio-Economic Analysis Committee. The associations argue this approach prevents the European Commission from understanding public and animal health impacts and urge ECHA to ensure dedicated assessment of the healthcare sector within the PFAS restriction process.

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

Life Sciences weekly highlights—30 October 2025

This week's edition of Life Sciences weekly highlights includes a Law360 analysis of the Court of Justice upholding a €60.5m fine against Teva and Cephalon in a long-running pay-for-delay case involving a generic version of a blockbuster narcolepsy treatment, and an MLex analysis reporting that the European Commission is considering changes to how the EU AI Act applies to products regulated under sector-specific legislation, such as medical devices, as part of a wider digital ‘omnibus’ package expected on 19 November 2025. Also included is news that MedTech Europe has called for EU rules changes to permit electronic instructions for use (eIFUs) for near-patient testing devices, also known as point-of-care (POC) testing, the MHRA announced a new AI-driven project to predict drug interaction side effects, and together with the Health Research Authority (HRA) outlined preparations for clinical trials reform due to take effect from 28 April 2026, including the establishment of an advisory group on simplified arrangements for consent in low intervention clinical trials, the EMA opened a consultation on the use of non-human primates in safety testing and implementation of the 3Rs (replacement, reduction and refinement) principles, as well as news that the Health Economics Methods Advisory (HEMA) has published its first draft report for public comment on the factors that should be considered in health technology assessment (HTA) and the MHRA Criminal Enforcement Unit dismantled the UK’s first major illicit manufacturing facility distributing unlicensed weight loss jabs, among other stories.

Team-NB adopts position paper on IVDR changes to companion diagnostic devices

The European Association of Medical Devices Notified Bodies (Team-NB) has unanimously adopted a comprehensive position paper during its General Assembly meeting. The guidance document establishes standardised interpretation guidelines for notified bodies to identify significant changes that may affect the performance, suitability, or intended use of companion diagnostic devices under the In Vitro Diagnostic Regulation (IVDR).